Merck

(IN BRIEF) DHL Group has appointed Maike Asmussen as Executive Vice President for Corporate Public Affairs, effective January 1, 2026. She joins from Merck, where she was Chief Political Officer, and brings over two decades of political and advocacy experience, … Read the full press release →

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review by the FDA for the first-line treatment of HER2-positive metastatic breast cancer. The application is supported by data from the … Read the full press release →

(IN BRIEF) Merck and Siemens have signed a new Memorandum of Understanding that expands their collaboration in life sciences and focuses on accelerating digital transformation across drug discovery, development, and manufacturing. The partnership integrates Merck’s life science SaaS tools and … Read the full press release →

(IN BRIEF) Merck has officially opened its first fully climate-neutral manufacturing facility in Cork, Ireland, with a €150 million investment that will create more than 200 jobs by 2028. The 3,000-square-meter site will produce advanced filtration devices essential for the … Read the full press release →

(IN BRIEF) Merck and mantro GmbH have established EdiMembre, Inc., a Massachusetts-based Deep Tech spin-out dedicated to advancing the alternative protein sector through Merck’s edible membrane technology. Designed to enable scalable production of structured cultivated meat and plant-based products, the … Read the full press release →

(IN BRIEF) The FDA has accepted AstraZeneca’s sBLA for Imfinzi as a perioperative immunotherapy regimen in resectable early‑stage and locally advanced gastric and GEJ cancers, granting Priority Review with a decision expected in Q4 2025. The application leverages MATTERHORN Phase III data … Read the full press release →

(IN BRIEF) Merck brought together top executives from Merck, Siemens, Intel, TRUMPF, and ZEISS in Darmstadt to highlight Europe’s critical contributions to the global semiconductor industry. With leading-edge capabilities in materials, lasers, optics, electronics, chip‑design software, and automation, these companies … Read the full press release →

(IN BRIEF) Merck has awarded its 2025 North American Advance Biotech Grant to Neoclease, a Boston-based startup developing AI-designed gene-editing therapies for Parkinson’s disease and other monogenic disorders. Neoclease will benefit from Merck’s technologies, contract testing, regulatory guidance, and hands-on … Read the full press release →

(IN BRIEF) Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significantly enhance Merck’s rare tumor portfolio, adding first-in-class therapies for desmoid tumors and NF1-PN. The deal aligns with Merck’s strategy … Read the full press release →

(IN BRIEF) The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherapy significantly improves event-free survival in patients with resectable gastric and gastroesophageal junction cancers compared to standard chemotherapy alone. Interim findings … Read the full press release →

(IN BRIEF) STMicroelectronics has signed its first physical Power Purchase Agreement (PPA) with TotalEnergies to secure renewable energy for its operations in France. The 15-year contract will deliver 1.5 TWh of clean power from two new wind and solar farms, … Read the full press release →

(IN BRIEF) Merck has partnered with NTU Singapore’s Digital Trust Centre (DTC) to advance digital trust technologies in industries requiring high security and compliance. The collaboration will deploy Merck’s digital-physical trust platform in Singapore, the first of its kind in … Read the full press release →

(IN BRIEF) Merck and Intel have launched a collaborative academic research initiative in Europe, bringing together eleven institutions from six countries. The program focuses on using Artificial Intelligence (AI) to make semiconductor manufacturing more sustainable, with research projects dedicated to … Read the full press release →

(IN BRIEF) Merck has officially opened a new €290 million biosafety testing facility in Rockville, Maryland, designed to meet the increasing global demand for biosafety testing services. This state-of-the-art facility consolidates various operations, including biosafety testing, analytical development, and cell … Read the full press release →

(IN BRIEF) TotalEnergies has signed a Power Purchase Agreement (PPA) with Saint-Gobain to supply renewable electricity to its facilities in France, starting in January 2026. This contract will provide 875 GWh of renewable energy over five years, sourced from TotalEnergies’ … Read the full press release →

(IN BRIEF) AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for treating patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have previously undergone endocrine therapy. … Read the full press release →

(IN BRIEF) Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, modular production systems. Siemens will become Merck’s preferred global supplier, providing advanced hardware and software solutions via the Siemens Xcelerator platform. The … Read the full press release →

(IN BRIEF) Merck has signed an MoU with Gene Therapy Research Institution Co., Ltd. (GTRI) to support the production of gene therapy for Parkinson’s Disease using Merck’s Sf-RVN® Insect Cell Line platform. This collaboration aims to enhance the manufacturing process … Read the full press release →

(IN BRIEF) Merck has joined the “Semiconductor-X” research project, a consortium led by Intel Germany and the Fraunhofer IFF, focusing on the digitalization of semiconductor supply chains to improve resilience and sustainability. The project, funded by the German Federal Ministry … Read the full press release →

(IN BRIEF) Merck and The Michael J. Fox Foundation (MJFF) are collaborating to advance Parkinson’s disease research using Merck’s SMCxPRO® immunoassay technology. This initiative aims to detect biomarkers indicating cell dysfunction in PD patients, enhancing research into new treatment options … Read the full press release →